comparemela.com

Latest Breaking News On - Jonathan barratt - Page 4 : comparemela.com

Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase ...

BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today

Leicester
United-kingdom
Stanford
Leicestershire
Long-island-jewish-medical-center
New-york
United-states
Brisbane
Queensland
Australia
American
America

Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024

08.01.2024 - BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) - Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today . Seite 1

New-york
United-states
Brisbane
Queensland
Australia
Richard-lafayette
Jonathan-barratt
Lotte-new-york-palace-hotel
Stanford-university-medical-center
University-of-leicester
Vera-therapeutics-inc
Nasdaq

Use of Povetacicept in Treatment of IgA Nephropathy

Drs Jonathan Barratt and Brad Rovin comment on clinical trial data regarding the use of povetacicept for the treatment of IgAN.

United-states
American
Brad-rovin
Jonathan-barratt
American-society-of-nephrology
American-society
Povetacicept
Wigan
Nephropathy
Proteinuria
Complement-inhibition
B-cell-modulation

The Future of IgA Nephropathy Treatment

Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD, discuss the future of IgAN treatment, highlighting the BlyS/APRIL axis.

Brad-rovin
Jonathan-barratt
Future-considerations
Wigan
Phase-3-clinical-trial-data
April
Blys-april
Povitacicept
Kdigo

Dual Inhibition of BlyS and APRIL in IgA Nephropathy

Nephrology experts explore the role of dual inhibition of BlyS and APRIL in the treatment of IgAN, and how this can impact disease pathogenesis.

Jonathan-barratt
Brad-rovin
Wigan
Nephropathy
Proteinuria
Complement-inhibition
B-cell-modulation
Blys-april-targeting

vimarsana © 2020. All Rights Reserved.